Abstract
KDM5 enzymes are H3K4 specific histone demethylases involved in transcriptional regulation and
DNA repair. These proteins are overexpressed in different kinds of cancer, including breast, prostate and
bladder carcinomas, with positive effects on cancer proliferation and chemoresistance. For these
reasons, these enzymes are potential therapeutic targets.
In the present study, we analyzed the effects of three different inhibitors of KDM5 enzymes in MCF-7
breast cancer cells over-expressing one of them, namely KDM5B/JARID1B.
In particular, compounds RS3195, RS3152, RS3183, R^5033 and RS4995 were assayed in terms of H3K4 demethylation (western blot), radio-sensitivity (cytoxicity and clonogenic assays) and damage accumulation (COMET assay and kinetics of H2AX phosphorylation) (Figure 1). We showed that three compounds can selectively inhibit
KDM5 enzymes and are capable of increasing sensitivity of breast cancer cells to ionizing radiation and
radiation-induced damage. These findings confirmed the involvement of H3K4 specific demethylases in
the response to DNA damage, showed a requirement of the catalytic function and suggested new
strategies for the therapeutic use of their inhibitors.
Original language | English |
---|---|
Title of host publication | Abstract Book |
Pages | 177 |
Number of pages | 1 |
DOIs | |
Publication status | Published - 2019 |
Event | XXVI National Meeting in Medicinal Chemistry - XII Young Medicinal Chemists’ Symposium - Milano Duration: 16 Jul 2019 → 19 Jul 2019 |
Conference
Conference | XXVI National Meeting in Medicinal Chemistry - XII Young Medicinal Chemists’ Symposium |
---|---|
City | Milano |
Period | 16/7/19 → 19/7/19 |
Keywords
- Cancer
- Drug Design
- JARID1B
- KDM5
- Small Molecules